Dornase in treatment of chronic bronchitis

Annals of Pharmacotherapy

Volumn 30, Issue 6, 1996, Pages 674-675

  Hudson, Teresa J ^a,b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYRIBONUCLEASE; PLACEBO;

ADULT; ARTIFICIAL VENTILATION; BRONCHIECTASIS; CHRONIC BRONCHITIS; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG TOLERANCE; FOLLOW UP; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RELAPSE; REVIEW; RISK FACTOR; TREATMENT PLANNING;

EID: 0030013330     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809603000616     Document Type: Review

References (21)

1. Package insert. Domase (dornase alfa). South San Francisco, CA: Genentech, August 1994.
2. Bone R. Cystic fibrosis. In: Wyngaarden JB, Smith LH, Bennett JC, eds. Cecil textbook of medicine. 19th ed. Philadelphia, PA: WB Saunders, 1992:418-21.
3. Potter JL, Specter S, Matthews LW, Lemm J. The nucleic acids in whole pulmonary secretions from patients with cystic fibrosis, bronchiectasis, and laryngectomy. Am Rev Respir Dis 1969;99:909-16.
4. Chernick WS, Barbero GJ. Composition of tracheobronchial secretions in cystic fibrosis of the pancreas and bronchiectasis. Pediatrics 1959;24: 739-45.
5. American Thoracic Society. A statement by the Committee on Diagnostic Standards for Nontuberculous Respiratory Diseases. Am Rev Respir Dis 1962;85:762-8.
6. Bone R. Bronchieclasis. In: Wyngaarden JB, Smith LH, Bennett JC, eds. Cecil textbook of medicine. 19th ed. Philadelphia, PA: WB Saunders, 1992:415-8.
7. Ferguson GT, Cherniack RM. Management of chronic obstructive pulmonary disease. N Engl J Med 1993;328:1017-22.
8. Aitken ML, Burke W, McDonald G, Shak S, Montgomery AB, Smith A. Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis. JAMA 1992;14:1947-51.
9. Salomon A, Herchfus JA, Segal MS. Aerosols of pancreatic dornase in bronchopulmonary disease. Ann Allergy 1954;12:71-9.
10. Segal MS, Goldstein M. Pancreatic dornase aerosols in bronchopulmonary disease. Ann N Y Acad Sci 1957;68:138-43.
11. Hubbard RC, McElvaney NG, Birrer P, Shak S, Robinson WW, Jolley C, et al. A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis. N Engl J Med 1992;326: 812-5.
12. Ramsey BW, Astley SJ, Aitken ML, Burke W, Colin AA, Dorkin HL, et al. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. Am Rev Respir Dis 1993;148:145-51.
13. Ranasinha C, Assoufi B, Shak S, Christiansen D, Fuchs H, Empey D, et al. Efficacy and safety of short-term administration of aerosolized recombinant human DNase I in adults with stable stage cystic fibrosis. Lancet 1993;342:199-202.
14. Fuchs HG, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994;331:637-42.
15. Ramsey BW, Dorkin HL for the Consensus Committee. Consensus conference: practical application of pulmozyme. Ped Pulmonol 1994;17: 404-8.
16. Wallace CA, Hall M, Kuhn RJ. Pharmacologic management of cystic fibrosis. Clin Pharm 1993;12:657-74.
17. Wilmott RW, Fiedler MA. Recent advances in the treatment of cystic fibrosis. Ped Clin North Am 1994;41:431-51.
18. Oster G, Huse DM, Lacey MJ, Regan MM, Fuchs HJ. Effects of recombinant human DNase therapy on healthcare use and costs in patients with cystic fibrosis. Ann Pharmacother 1995;29:459-64.
19. Thompson AB, Fuchs H, Corkery K, Pun E, Fick RB, Rennard SI, et al. Phase II trial of recombinant human DNase for the therapy of chronic bronchitis (abstract). Am Rev Respir Dis 1993;147(4 pt 2):A318.
20. Pick RB, Anzueto A, Mahutte K, members of the rhDNase-COPD Study Group. Recombinant DNase mortality reduction in acute exacerbations of chronic bronchitis (abstract). Clin Res 1994;42:294A.
21. Medi-Span hospital formulary pricing guide. Indianapolis, IN: MediSpan, April 1995.